论文部分内容阅读
目的探讨吡拉西坦联合尼莫地平治疗脑梗死后血管性痴呆(Va D)患者的临床效果。方法资料选取2013年8月至2014年8月收治的84例脑梗死后Va D患者,按照完全抽样法将患者1:1分为两组,对照组患者予以尼莫地平治疗,研究组患者在对照组治疗基础上加用吡拉西坦,比较两组患者治疗前后的认知障碍评分与生活能力评情况,并分析两组患者的不良反应发生情况。结果治疗前两组患者认知障碍评分与生活能力评分差异均无统计学意义,治疗后研究组患者两项评分均优于对照组,差异均有统计学意义(均P<0.05)。两组患者用药不良反应包括头晕、皮肤潮红、血压下降与乏力等,两组不良反应发生率比较差异无统计学意义(P>0.05)。结论吡拉西坦联合尼莫地平治疗脑梗死后Va D具有明显的临床效果,可有效改善患者的认知功能障碍,并提升其生活能力,且无明显不良反应发生。
Objective To investigate the clinical effect of piracetam combined with nimodipine in the treatment of patients with vascular dementia (Va D) after cerebral infarction. METHODS: Eighty-four VaD patients with cerebral infarction were enrolled in the study from August 2013 to August 2014. The patients were divided into two groups according to the method of complete sampling, while those in the control group were treated with nimodipine. The patients in the study group were treated with The patients in the control group were treated with piracetam. The scores of cognitive impairment and the viability of the two groups before and after treatment were compared, and the incidence of adverse reactions in both groups were analyzed. Results There was no significant difference in cognitive impairment score and life ability score between the two groups before treatment. After treatment, both scores of the study group were better than those of the control group (all P <0.05). Two groups of patients adverse drug reactions, including dizziness, skin flushing, blood pressure decreased and fatigue, the incidence of adverse reactions was no significant difference between the two groups (P> 0.05). Conclusion Piracetam combined with nimodipine has obvious clinical effect on VaD after cerebral infarction, which can effectively improve patients’ cognitive dysfunction and enhance their living ability without obvious adverse reactions.